An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer

Trial Profile

An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Afuresertib (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms AKTRES
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results assessing maximum tolerated dose in phase I portion and efficacy in phase II portion of the study presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 22 Dec 2014 Planned number of patients changed from 43 to 60 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top